Febre hemorrágica viral causada pelo vírus Lassa, transmitido pelo contato com roedores infectados; é caracterizada por febre, dor de cabeça, mal-estar, mialgia e perda auditiva.
Introdução
O que você precisa saber de cara
Febre hemorrágica viral causada pelo vírus Lassa, transmitido pelo contato com roedores infectados; é caracterizada por febre, dor de cabeça, mal-estar, mialgia e perda auditiva.
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 15 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 27 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Nenhum gene associado encontrado
Os dados genéticos desta condição ainda estão sendo catalogados.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Febre de Lassa
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
🟢 Recrutando agora
4 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
20 ensaios clínicos encontrados, 6 ativos.
Publicações mais relevantes
Mostrando amostra de 200 publicações de um total de 752
Development of a Conditional Replication System Using a Lassa Virus Glycoprotein Complex-Encoding Retroviral Vector for Isolating Resistant Variants to Inhibitors in BSL-2.
A high-risk infectious disease or a Category A pathogen, Lassa virus (LASV), requires strict containment, classified as biosafety level 4 (BSL-4) conditions, which restricts research on the virus due to the scarcity of BSL-4 facilities. Thus, replication-defective pseudotyped retroviral vectors have been widely used as safe materials for neutralizing activity assays of drugs and antibodies in BSL-2. Here, we established a novel retroviral vector system encoding LASV glycoprotein complex (GPC) that can exclusively replicate in cells expressing the Gag-Pol protein of murine leukemia virus (MLV) under BSL-2 conditions. Using this conditional replication system, we successfully isolated LASV GPC variants resistant to either an anti-LASV compound, lamellarin α 20-sulfate, or a neutralizing antibody derived from a Lassa fever survivor. In the lamellarin α 20-sulfate-resistant variants, K125E and H13R amino acid substitutions cooperatively conferred resistance. The K125E enhanced infectivity and simultaneously conferred a lethal effect on cells in the conditional replication system, while the H13R mitigated the latter effect, thereby enabling stable expression of LASV GPC in cells. In the neutralizing antibody-resistant variants, I403T substitution was responsible for the resistance by impairing antibody binding. This study provides a valuable BSL-2-based platform for isolating LASV GPC variants resistant to inhibitors and characterizing their mutations.
Post-discharge sequelae of Lassa fever survivors in Nigeria: an analysis of the LASCOPE prospective cohort.
Lassa fever is one of the most important viral haemorrhagic fevers, yet post-discharge sequelae remain inadequately characterised. Previous studies have been limited by small sample sizes and unsystematic assessments. We aimed to describe post-discharge sequelae in Lassa fever survivors and explore the effect of disease severity on sequelae patterns. LASCOPE was a prospective study of patients with PCR-confirmed Lassa fever hospitalised at Federal Medical Centre Owo, Owo, Nigeria, between April 23, 2018, and Feb 17, 2023. All patients who provided informed consent were included, with no age restriction. Severe disease was defined as the presence of at least one of the following during the acute phase: National Early Warning Score version 2 score of 7 or higher, Kidney Disease Improving Global Outcomes stage 2 or higher, or Lassa virus PCR Ct value of less than 25. At hospital discharge, follow-up of survivors was planned for day 60 after admission, or before that, based on medical need. A systematic symptom assessment was done at each visit. The main outcome was clinical remission, defined as complete absence of symptoms. Other outcomes were post-discharge death, symptom incidence, and prevalence of symptoms over time. Subgroup analyses were performed by age group (children aged <18 years or adults aged ≥18 years) and disease severity (severe or not severe). Of 882 survivors (median age 32 years [IQR 22-46], 459 [52%] female and 423 [48%] male), post-discharge data were available for 807 (91%), with a total of 2603 person-months of follow-up. For three of 807 survivors with post-discharge information, only the vital status was collected. 736 (91%) of 807 reached clinical remission, with a median time to clinical remission of 19 days (95% CI 16-23) post discharge. The most frequently reported symptoms were asthenia (158 [20%] of 804), headache (148 [18%]), and post-exertional malaise (123 [15%]). Hearing symptoms were reported by only 17 (2%) of 804 survivors, which was substantially lower than previous studies. Disease severity did not affect time to remission. Six (1%) survivors died after hospital discharge. Patient-reported symptoms suggest good recovery with few hearing or neurosensory disorders in most survivors of Lassa fever. Future research would benefit from extended follow-up periods and standardised diagnostic assessments, including objective audiometry, to further characterise the full spectrum of post-Lassa fever complications. Institut National de la Santé et de la Recherche Médicale, University of Oxford, EU, UK Department for International Development, Wellcome Trust, French Ministry of Foreign Affairs, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales, and French National Research Institute for Sustainable Development.
Agnostic capture of pathogens for the detection and diagnostics of emerging threats.
The continued emergence of pathogens, whether novel, re-emerging, or engineered, poses a persistent global biosecurity and public health challenge. Recent outbreaks, including COVID-19, Lassa fever, Marburg virus, mpox, and avian influenza, underscore the urgent need for robust systems that enable rapid surveillance, early diagnosis, and timely countermeasures before widespread human transmission occurs. In this article, we focus on early detection technologies and systematically evaluate current diagnostic and sensing modalities. We highlight sequencing and spectroscopy as two complementary approaches capable of providing broad, agnostic detection and rich biological insight. Our analysis emphasizes that scientific innovation alone is insufficient: effective preparedness also requires improved data curation, integration, and sharing to build AI-ready resources that accelerate future responses. We argue for coordinated advances in both technological capabilities and supporting infrastructure to enable the rapid identification and characterization of emerging pathogens and to fully leverage modern science against evolving infectious threats.
Health-economic impacts of age-targeted and sex-targeted Lassa fever vaccination in endemic regions of Nigeria, Guinea, Liberia, and Sierra Leone: a modelling study.
Lassa fever is an emerging zoonotic disease endemic to west Africa. Several vaccines aimed at preventing Lassa fever are currently under development, creating a need to assess how best to administer them once licensed for human use. We aimed to project the health-economic burden of Lassa fever from 2025 to 2037 across age and sex groups in subnational administrative divisions of west Africa with endemic Lassa mammarenavirus transmission and to estimate the cost-effectiveness of targeting Lassa vaccination to different risk groups. In this vaccine-impact modelling study, we developed a mathematical model using a zoonosis risk map and epidemiological data from recent and ongoing cohort studies to predict the health-economic burden of Lassa fever across age and sex groups in endemic regions. We simulated vaccination campaigns targeting different risk groups to estimate the cost-effectiveness of various strategies for Lassa vaccine administration. Threshold vaccine costs (TVCs), which represent the break-even price per dose of vaccine administered, were estimated in international dollars (INT$ 2023), accounting for health-care costs, productivity losses, and monetised disability-adjusted life-years (DALYs) averted by vaccination. Lassa fever was estimated to cause 6·23 (95% uncertainty interval (UI) 4·21-8·42) hospitalisations, 0·75 (0·48-1·10) deaths and 31·1 (17·7-52·2) DALYs per 100 000 person-years. Vaccine strategies targeting adolescents-adults aged 15-49, older adults aged 50 years and older, and women of childbearing age (WCBA) aged 15-49 years prevented, respectively, the most hospitalisations, deaths, and DALYs per 100 000 vaccine doses. Under base case assumptions, the most cost-effective strategy (greatest net monetary benefit) was untargeted vaccination for a vaccine costing INT$2 per dose, and targeting adolescents-adults at $5 per dose. At $10 per dose or more, none of the considered strategies were cost-effective. The highest TVC for a single-dose vaccine was estimated at $7·39 (95% UI 4·33-11·60) when targeting adolescents-adults, followed by $6·69 (4·17-9·85) when targeting older adults, $6·10 (3·56-9·74) when targeting WCBA, and $1·94 (1·10-3·10) when targeting children. Targeting of adolescents-adults appears to generate the greatest health-economic value per vaccine dose. However, the most cost-effective vaccination strategy will depend on vaccine price. Coalition for Epidemic Preparedness Innovations.
Lassa fever symptomatology, viral dynamics, and host immune response (PREPARE): a prospective, observational cohort study in Liberia.
Lassa virus (LASV) is a persistent threat to public health in west Africa and beyond. LASV is endemic in west Africa and each year it is responsible for an estimated 2·7 million infections, 23 700 hospitalisations, and 5000 deaths. With over 32 reported cases of Lassa fever imported into non-endemic countries-one-third of which were fatal-the importance of enhanced detection and management of Lassa fever extends beyond west Africa. The prevalence, pathogenesis, and persistence (PREPARE) study was a prospective cohort study among patients admitted to two hospitals in a hyperendemic area of Liberia. Any patients aged 5 years or older with a febrile illness were eligible to enrol and be tested for Lassa fever. The study aimed to measure the prevalence of LASV infection and assess the signs and symptoms, LASV viral replication kinetics, and LASV-specific IgM and IgG responses longitudinally among adults and children with laboratory-confirmed Lassa fever. From July 10, 2018, to Aug 12, 2024, a total of 435 participants were enrolled, including 362 admitted with a febrile illness and 73 who were directly admitted with clinical suspicion for Lassa fever. Lassa fever was diagnosed by plasma LASV RT-PCR in 41 (11%) of 362 febrile participants and 47 (64%) of 73 participants directly admitted with suspected Lassa fever, resulting in a total of 88 cases of confirmed Lassa fever. At entry, anorexia (71 [81%] of 88 vs 178 [51%] of 347), severe fatigue or weakness (63 [72%] vs 178 [51%]), and nausea or vomiting (39 [44%] vs 95 [27%]) were more likely to be reported by participants with Lassa fever than by participants who tested LASV RNA negative. Among the participants with Lassa fever, 11 (13%) of 88 died after admission. Mental status changes, seizures, acute kidney failure, hyperkalaemia, and metabolic acidosis were more frequent in patients with Lassa fever who died than in patients who survived. Median cycle threshold values at study entry for glycoprotein complex gene (GPC) or polymerase gene (L) were lower in those who died (GPC cycle threshold 22·4 [IQR 20·0-27·9]; L cycle threshold 21·7 [19·0-27·7]) than in those who survived (GPC cycle threshold 31·5 [28·0-33·9]; L cycle threshold 32·3 [28·0-33·9]). Among the 70 participants with Lassa fever who consented to longitudinal follow-up through their hospitalisation, seven died and these participants tended to have lower cycle threshold values and lower IgM and IgG LASV responses compared with survivors. In a region of Liberia where it is endemic, Lassa fever is a prevalent cause of morbidity and mortality. Several symptoms were more likely in those with Lassa fever but overlap with those caused by other common infectious diseases. Compared with survivors, those who died during hospitalisation for Lassa fever tended to have evidence of organ dysfunction along with higher viral loads at study entry and during follow-up and lower antibody levels during their illness, suggesting a muted humoral immune response might be a factor in the development of severe Lassa fever. US National Institute of Allergy and Infectious Diseases and National Institutes of Health.
Publicações recentes
The virus entry inhibitor ARN-75039 provides therapeutic protection against Lassa virus infection in guinea pigs.
Neural network modeling of Lassa fever spread and disability effects.
B cell immunity to the Lassa virus glycoprotein is a correlate of vaccination-induced virus control in mice.
Post-acute sequelae after Lassa fever: A systematic review and meta-analysis.
Development of a broad-lineage Lassa virus rapid diagnostic test informed by the WHO REASSURED framework.
📚 EuropePMC747 artigos no totalmostrando 197
[Immunosuppression and severe Lassa fever].
Medecine sciences : M/SDevelopment of a Conditional Replication System Using a Lassa Virus Glycoprotein Complex-Encoding Retroviral Vector for Isolating Resistant Variants to Inhibitors in BSL-2.
International journal of molecular sciencesImpact of seasonal changes on the epidemiology of Lassa fever in a state in North Central, Nigeria.
Tropical diseases, travel medicine and vaccinesPost-discharge sequelae of Lassa fever survivors in Nigeria: an analysis of the LASCOPE prospective cohort.
The Lancet. Infectious diseasesImproving Lassa fever risk mapping using self-organizing maps and spatial determinants.
Acta tropicaEtiologies of community-acquired febrile illness identified by TaqMan Array Card qPCR on blood samples: a systematic review and meta-analysis.
Journal of clinical microbiologyMetagenomic surveillance of undiagnosed febrile illness in Nigeria does not reveal the etiological agent for most patients.
bioRxiv : the preprint server for biologyCharacterization of conserved residues in the mammarenavirus matrix protein Z using novel Lassa virus life cycle modelling assays.
Scientific reportsAgnostic capture of pathogens for the detection and diagnostics of emerging threats.
iScienceAssessment of healthcare worker preparedness and health literacy for Marburg virus disease in Nigeria: A cross-sectional study.
Southern African journal of infectious diseasesSystematic review protocol: evaluation of candidate platforms and vaccines for emerging and re-emerging viral threats.
Systematic reviewsHealth-economic impacts of age-targeted and sex-targeted Lassa fever vaccination in endemic regions of Nigeria, Guinea, Liberia, and Sierra Leone: a modelling study.
The Lancet. Global healthLassa fever symptomatology, viral dynamics, and host immune response (PREPARE): a prospective, observational cohort study in Liberia.
The Lancet. Infectious diseasesOral 4'-fluorouridine rescues nonhuman primates from advanced Lassa fever.
NatureGuinea Pig Model for Lassa Virus Infection of Reproductive Tract and Considerations for Sexual and Vertical Transmission.
Emerging infectious diseasesA One Health trial design to accelerate Lassa fever vaccines.
Nature medicineA Systematic Review on the Economic Burden of the Most Prevalent Infectious Diseases in West Africa.
Health science reportsInactivation of Ebola, Nipah, and Lassa viruses in tissue using neutral buffered formalin, MagMAX lysis/binding solution, or TriPure isolation reagent.
Scientific reportsA promising therapeutic approach for post-Lassa fever sensorineural hearing loss: a case report.
Oxford medical case reportsSerological evidence of concurrent Lassa virus and SARS-CoV-2 exposure in Ghana- a cross-sectional study.
BMC infectious diseasesEfficacy, safety, and immunogenicity of Lassa fever vaccines: A living systematic review and landscape analysis of vaccine candidates.
PloS oneViral zoonotic disease outbreaks and response strategies in Sub-Saharan Africa: a scoping review.
One health outlookIn-silico investigations of bioactive compounds from ginger against Lassa fever virus nucleoprotein.
Scientific reportsOne Health, Many Gaps: Rethinking Epidemic Intelligence in Resource-Limited Settings to Prepare for the Global Threat of Disease X.
MicroorganismsPresence of Lassa Virus RNA in Cerebrospinal Fluid Indicating Neuroinvasive Lassa Fever in Pediatric Patients From Edo State, Nigeria.
The Journal of infectious diseasesGenome diversity and evolutionary understanding of Lassa virus: a holistic approach highlighting a potential target for cross-lineage vaccine development.
Archives of virologyLand use gradients drive spatial variation in Lassa fever host communities in the Eastern Province of Sierra Leone.
The Journal of animal ecologyDescriptive Epidemiology of Acute Febrile Illness Patients in Nigeria: Pathogens of Global Public Health Significance Detected Using a Multi-Pathogen Detection Tool.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaO'nyong'nyong Virus Infections in Nigeria: A Case Series.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaViral hemorrhagic fevers - therapeutic trial advances and challenges.
Expert review of anti-infective therapyA Mammarenavirus Close to Lassa Virus in a Patient with Meningoencephalitis.
The New England journal of medicineSafety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults.
Frontiers in immunologySafety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate.
The New England journal of medicineSocioeconomic and environmental predictors of lassa fever transmission in Lower Bambara Chiefdom, Kenema District, Eastern Sierra Leone.
BMC public healthHarnessing traditional healers role in strengthening Africa's public health response: A case study of Mpox outbreak.
PLoS neglected tropical diseasesSerological Evidence of Lassa Virus Exposure in Non-Mastomys Small Mammals Within a Hyperendemic Region of North-Central Nigeria: A Pilot Study.
VirusesClinical Outcomes of Severe Lassa Fever in West Africa: A Systematic Review and Meta-Analysis.
International journal of environmental research and public healthLandscape analysis of Lassa virus diagnostic tests: Challenges, innovations and future directions.
Diagnostic microbiology and infectious diseaseWhole-genome sequencing of Lassa virus from dry blood spots: a comparative evaluation.
Infectious diseases of povertyLARGE1 processively polymerizes length-controlled matriglycan on prodystroglycan.
Nature communicationsImmunogenicity of a trivalent haemorrhagic fever vaccine candidate against Sudan virus, Marburg virus and Lassa virus in an mpox vaccine.
The Journal of general virologyRevealing hidden drivers of Lassa fever through a model-informed approach for reproducing and predicting disease dynamics and guiding control strategies.
Scientific reportsLassa fever: A comprehensive review of virology, clinical management, and global health implications.
World journal of virologyCD4+ and CD8+ T cells are not the main driver of Lassa fever pathogenesis in macaques.
JCI insightAn orally available 4'-fluorouridine prodrug inhibits SFTSV and LCMV infection.
Journal of virologyCLASV: Rapid Lassa virus lineage assignment with random forest.
PLoS neglected tropical diseasesRobust polyfunctional CD8+ and CD4+ T cell responses in HLA-A*0201/DR1 transgenic mice following vaccination with modified vaccinia virus Ankara-based vaccines delivering Lassa virus glycoprotein or nucleoprotein.
The Journal of general virologyAerostability of Sin Nombre Virus Aerosol Related to Near-Field Transmission.
Pathogens (Basel, Switzerland)Lassa fever in West Africa: a systematic review and meta-analysis of attack rates, case fatality rates and risk factors.
BMC public healthLicoisoflavone B and glabridin from Glycyrrhiza glabra as potent nucleoprotein antagonists of Lassa virus: insights from molecular docking, dynamics simulation, PCA, and DFT studies.
Journal, genetic engineering & biotechnologyIn-silico screening of small compounds against Lassa fever haemorrhagic virus nucleoprotein.
Scientific reportsLassa fever in Bauchi State, Nigeria: communication channels and health-seeking behavior.
IJID regionsAI-driven diagnosis of Lassa fever: Evidence from Nigerian clinical records.
Computational biology and chemistryModelling the effects of climate and human factor on Lassa fever distribution in Ondo State Nigeria.
International journal of biometeorologyLassa fever in African green monkeys: Clinical disease and fatal outcome are associated with systemic viral dissemination and inflammation.
Cell reports. MedicineThe Biological Characteristics and Mouse Model of Lassa Virus From the First Imported Case in China.
MedCommProspective cohort study to evaluate Lassa fever incidence, symptoms and coinfection with malaria in West Africa: the Enable Lassa Research Programme ('ENABLE 1.5') - study protocol.
BMJ public healthThe resurgence of Lassa fever in Nigeria: economic impact, challenges, and strategic public health interventions.
Frontiers in public healthEstimation of Lassa fever incidence rates in West Africa: Development of a modeling framework to inform vaccine trial design.
PLoS neglected tropical diseasesIntersectoral collaboration in zoonotic disease surveillance and response: A One Health study in the Greater Accra metropolitan area of Ghana.
One health (Amsterdam, Netherlands)The significance of studying high-consequence pathogens in their natural reservoirs.
Advances in virus researchA template tool for the evaluation of vaccines for emerging pathogens to be used for pregnant and breast-feeding women.
VaccineA global living systematic review and meta-analysis hub of emerging vaccines in pregnancy and childhood.
Reproductive healthSafety Toxicology Study of Reassortant Mopeia-Lassa Vaccine in Guinea Pigs.
Future pharmacologyContinuous vital sign monitoring of acute Lassa fever using wearable biosensor devices in West Africa.
Communications medicineInfection prevention and control measures for emerging infectious disease: lessons learned from the first case of imported Lassa fever in China.
Antimicrobial resistance and infection controlLassa fever survivors: long-term health effects and chronic sequelae - a scoping review.
BMC infectious diseasesA rapid LASV detection method based on CRISPR-Cas13a and recombinase aided amplification with special lateral-flow test strips.
Scientific reportsAssessing the Potential of Sexual Transmission of Lassa Virus in a Natural Rodent Reservoir.
The Journal of infectious diseasesIdentification of Factors Contributing to Pathogenic Variability Among Lassa Virus Strains Using the Guinea Pig Model and Reverse Genetics.
The Journal of infectious diseasesA Review of the Epidemiology of Lassa Fever in Nigeria.
MicroorganismsClimate Change and the Rise of Emerging and Re-Emerging Infectious Diseases in Africa: A Literature Review.
International journal of environmental research and public healthDrivers of Lassa fever in an endemic area of southwestern Nigeria (2017-2021): An epidemiological study.
PloS oneA systematic review of the immuno-inflammatory dysfunction secondary to viral hemorrhagic fevers; Ebola and Lassa fever.
PLoS neglected tropical diseasesInfusion of neutralization into Lassa vaccine design.
Trends in immunologyDeveloping digital learning to help reduce laboratory inequalities: a viral haemorrhagic fever case study.
One health outlookSerosurveillance Identifies an Endemic Hotspot of Lassa Fever in Faranah, Upper Guinea.
The Journal of infectious diseasesNigeria's public health response to disease outbreaks: A review of strengths and weaknesses.
Journal of public health in AfricaEpidemiological characteristics and hospital outcomes of hospitalized Lassa fever cases during the 2022-2023 outbreak in Liberia.
F1000ResearchImpact of seasonal change on virus-rodent dynamics in Nigeria's Edo-Ondo hotspot for Lassa fever.
Current research in parasitology & vector-borne diseasesElectrocardiographic alterations in patients treated for acute Lassa Fever: Description of results from a phase II clinical trial in Nigeria.
Journal of infection and public healthLassa fever outbreak in West Africa: Rising regional cases with global implications.
Journal of infection and public healthLassa Virus Infection of Primary Human Airway Epithelial Cells.
VirusesEstablishment of a Lassa Fever Specimen Biobank in Nigeria.
The American journal of tropical medicine and hygieneAssessment of knowledge, attitudes, and practices of bushmeat value chain actors in Nigeria toward mpox and other zoonoses.
Frontiers in veterinary scienceThe First Imported Case of Lassa Fever - China, 2024.
China CDC weeklyGenomic changes of Lassa virus associated with mammalian host adaptation.
BMC genomicsA Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa fever.
VaccineThe epidemiology of Lassa fever in Ghana: a study on the 2023 Lassa fever outbreak in Ghana.
Frontiers in public healthEpidemiological analysis of Lassa fever control using novel mathematical modeling and a dual-dosage vaccination approach.
BMC research notesDetection of Immunoglobulin G and/or IgM antibodies specific for Lassa virus among HIV patients in the Northwestern region of Cameroon.
Virology journalAssessing the Environmental Drivers of Lassa Fever in West Africa: A Systematic Review.
VirusesEvaluation of the diagnostic accuracy of the ReLASV Pan-Lassa Antigen Rapid Test for Lassa Fever in Nigeria.
PLOS global public healthExpansion of myeloid suppressor cells and suppression of Lassa virus-specific T cells during fatal Lassa fever.
PLoS pathogensLaboratory Diagnosis and Molecular Epidemiological Characterization of the First Imported Case of Lassa Fever in China.
Biomedical and environmental sciences : BESThe First Imported Case of Lassa Fever in China - Implications for Global Health Surveillance.
Biomedical and environmental sciences : BESSafety, immunogenicity, efficacy, and effectiveness of Lassa fever vaccines in pregnant persons, children, and adolescents: a protocol for a living systematic review and meta-analysis.
Reproductive healthCoadministration of ribavirin and arenaviral entry inhibitor LHF-535 enhances antiviral benefit against authentic lassa virus.
Virologica SinicaNotes from the Field: Response to a Case of Travel-Associated Lassa Fever - Iowa, October-November 2024.
MMWR. Morbidity and mortality weekly reportMapping the antibody response to Lassa virus vaccination of non-human primates.
EBioMedicinePreclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials.
EBioMedicineBuilding climate-resilient health systems in Sierra Leone: addressing the dual burden of infectious and climate-related diseases.
Infectious diseases of povertyThe Critical Role of Otolaryngologists in Managing Lassa Fever Sequelae: A Call for Action.
Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-facialeCases of high-consequence infectious diseases identified in the UK, 1962-2023.
Journal of medical microbiologyUK authorities are "working at speed" to trace contacts of Lassa fever case.
BMJ (Clinical research ed.)Advancing the frontiers of virology in Africa: The African Virologists Network's Mission and Progress.
VirologyKnowledge, perception and preventive practices of Lassa fever among mothers of under-five children in an endemic community in Edo State, Nigeria.
BMC public healthLassa virus protein-protein interactions as mediators of Lassa fever pathogenesis.
Virology journalStructure-guided design of a prefusion GPC trimer induces neutralizing responses against LASV.
NPJ vaccinesAdaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics.
Emerging infectious diseasesPrimary HIV-1 infection presenting with nephrotic-range proteinuria and severe acute kidney injury mimicking imported Lassa fever.
InfectionSafe in Pregnancy and Safe in Children: Global Living Systematic Reviews and Meta-analyses Hub for Emergency Vaccines.
The Pediatric infectious disease journalPlasma zinc and selenium levels in adult inpatients with Lassa fever in Nigeria: A case-controlled study.
IJID regionsAppraisal of World Health Organization guidelines for priority infectious diseases with potential to cause public health emergencies.
Public healthC-reactive protein and association with disease severity in hospitalized adult patients with Lassa fever in Nigeria.
IJID regionsEnhancing surveillance for dengue fever in Oyo State, Nigeria - a one health approach.
One health outlookFlunarizine as a Candidate for Drug Repurposing Against Human Pathogenic Mammarenaviruses.
VirusesThe first imported case of Lassa fever in China: a case description.
Quantitative imaging in medicine and surgeryAnalysis of synonymous codon usage bias of Lassa virus.
Virus researchKnowledge, attitude and practice of Lassa fever prevention among adults in Bali Local Government Area, Taraba State, Nigeria.
Journal of preventive medicine and hygieneCurrent perspectives on vaccines and therapeutics for Lassa Fever.
Virology journalDescriptive epidemiology of Lassa fever, its trend, seasonality, and mortality predictors in Ebonyi State, South- East, Nigeria, 2018-2022.
BMC public healthSystematic Review and Meta-Analysis of Female Reproductive Health Following Ebola Virus Disease.
The American journal of tropical medicine and hygieneU-73122, a phospholipase C inhibitor, impairs lymphocytic choriomeningitis virus virion infectivity.
The Journal of general virologyFatal Lassa fever in cynomolgus monkeys is associated with systemic viral dissemination and inflammation.
PLoS pathogensMolecular detection of dengue virus from febrile patients in Ghana.
BMC infectious diseasesQuantification of heterogeneity in human CD8+ T cell responses to vaccine antigens: an HLA-guided perspective.
Frontiers in immunologyChallenges Associated With Re-Emergence of Lassa Fever in Nigeria: An Exploratory Study of Epidemiology, Phylogenomics, and Recommendations Toward Its Eradication.
Health science reportsThe DNA-based Lassa vaccine INO-4500 confers durable protective efficacy in cynomolgus macaques against lethal Lassa fever.
Communications medicineReport of a SPEAC webinar 22 september 2023: Sensorineural hearing loss, lassa virus disease and vaccines.
VaccineLassa fever outbreaks, mathematical models, and disease parameters: a systematic review and meta-analysis.
The Lancet. Global healthIdentifying risk factors for clinical Lassa fever in Sierra Leone, 2019-2021.
Epidemiology and infectionApplication of an Integrated Risk Matrix and the Borda Count Method on Lassa Fever in Assessing the Importation Risk of EID - 9 African Countries, 1996-2023.
China CDC weeklyA Lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigs.
NPJ vaccinesLassa fever in Nigeria: epidemiology and risk perception.
Scientific reportsDiscovering Lassa virus nucleoprotein inhibitors via in silico drug repositioning approach.
Journal of biomolecular structure & dynamicsA validated and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA virus neutralising antibodies for vaccine development and comparison.
F1000ResearchBurden of Lassa fever disease in pregnant women and children and options for prevention.
VaccineUS resident died from Lassa fever probably contracted in West Africa.
BMJ (Clinical research ed.)Lassa virus persistence with high viral titers following experimental infection in its natural reservoir host, Mastomys natalensis.
Nature communicationsVirus Load Kinetics in Lassa Fever Patients Treated With Ribavirin: A Retrospective Cohort Study From Southern Nigeria.
Open forum infectious diseasesA conceptual learning analysis of paired after action and intra action reviews for health emergencies.
Learning health systemsPathological Insights into Lassa Virus-Induced Vestibular Dysfunction in Mice: Histopathological Analysis of the Inner Ear Vestibular Apparatus.
The Journal of infectious diseasesChallenges associated with the implementation of institutional quarantine and isolation strategies during major multicountry viral outbreaks in Africa (2000-2023): a scoping review.
Global health research and policyEnabling laboratory readiness and preparedness for the evaluation of suspected viral hemorrhagic fevers: development of a laboratory toolkit.
Infection control and hospital epidemiologySeroprevalence and risk factors for Lassa virus infection in South-West and North-Central Nigeria: a community-based cross-sectional study.
BMC infectious diseasesElectroencephalography in emerging viral infections: Lessons learned from implementing an EEG unit in a Lassa fever isolation ward in Nigeria.
PLoS neglected tropical diseasesApplied One Health: Nigeria National Veterinary Research Institute COVID-19 pandemic response.
The Onderstepoort journal of veterinary researchInactivation Validation of Ebola, Marburg, and Lassa Viruses in AVL and Ethanol-Treated Viral Cultures.
VirusesEmerging patterns in rodent-borne zoonotic diseases.
Science (New York, N.Y.)Characterization of bi-segmented and tri-segmented recombinant Pichinde virus particles.
Journal of virologyAn ordered mesoporous carbon-silica hybrid for the detection of the antiviral drug ribavirin in clinical samples.
Nanoscale advancesDefining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responses.
Cell reportsClinical Management of Hospitalized Patients With High-Consequence Infectious Diseases in England.
Health securityPreclinical Safety Assessment of the EBS-LASV Vaccine Candidate against Lassa Fever Virus.
VaccinesHealth and economic impacts of Lassa vaccination campaigns in West Africa.
Nature medicineLassa Fever: Critical Review and Prospects for Control.
Tropical medicine and infectious diseasePresentation and Outcomes of Lassa Fever in Children in Nigeria: A Prospective Cohort Study (LASCOPE).
Journal of the Pediatric Infectious Diseases SocietyQuantifying the risk of spillover reduction programs for human health.
PLoS computational biologyViral vector- and virus-like particle-based vaccines against infectious diseases: A minireview.
HeliyonInactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease.
NPJ vaccinesDeciphering the enigma of Lassa virus transmission dynamics and strategies for effective epidemic control through awareness campaigns and rodenticides.
Scientific reportsDouble stigma: a cross-sectional study of Lassa patients with hearing loss in North Central Nigeria.
Frontiers in public healthAptamer and aptasensor technology for diagnosis of infectious diseases: A mini review.
Indian journal of medical microbiologyModelling Lassa virus dynamics in West African Mastomys natalensis and the impact of human activities.
Journal of the Royal Society, InterfaceDeep mutational scanning reveals functional constraints and antibody-escape potential of Lassa virus glycoprotein complex.
ImmunityAddressing bottlenecks in Lassa fever treatment: overcoming the ribavirin parenteral formulation challenge.
Tropical medicine and healthHand hygiene among oral health care providers in public institutions in Edo state even in the wake of Lassa fever.
African health sciencesLassa fever research priorities: towards effective medical countermeasures by the end of the decade.
The Lancet. Infectious diseasesCoadministration of LHF-535 and favipiravir protects against experimental Junín virus infection and disease.
Antiviral researchLASSA FEVER IN INTERNALLY-DISPLACED PERSONS' CAMP: A CASE REPORT AT ZABARMARI, BORNO STATE, NIGERIA.
Annals of Ibadan postgraduate medicinePotent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse.
PLoS pathogensAssignment of the Lassa virus transmembrane domain in the prefusion and postfusion states in detergent micelles.
Biomolecular NMR assignmentsAnalysing the association between perceived knowledge, and attitudes on Lassa Fever infections and mortality risk factors in lower Bambara Chiefdom.
BMC public healthIdentification of residues in Lassa virus glycoprotein 1 involved in receptor switch.
Virologica SinicaA systematic review of mathematical models of Lassa fever.
Mathematical biosciencesIdentification of a macrocyclic compound targeting the lassa virus polymerase.
Antiviral researchIntrasegmental recombination as an evolutionary force of Lassa fever virus.
Frontiers in microbiologyUnraveling factors responsible for pathogenic differences in Lassa virus strains.
bioRxiv : the preprint server for biologyDigitalizing disease surveillance: experience from Sierra Leone.
Health policy and planningHexestrol, an estrogen receptor agonist, inhibits Lassa virus entry.
Journal of virologyEbola Virus-Specific Neutralizing Antibody Persists at High Levels in Survivors 2 Years After Resolution of Disease in a Sierra Leonean Cohort.
The Journal of infectious diseasesAn mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice.
Journal of virologyA novel BSL-2 Lassa virus reverse genetics system modelling the complete viral life cycle.
Emerging microbes & infectionsThe Perspectives of Healthcare Professionals on the Strategies, Challenges, and Community Responses to Health System Response and Interventions Towards Lassa Fever Infections and Mortality in Sierra Leone.
Risk management and healthcare policyRapid diagnostic tests for Lassa fever: what do we aim for?
The Lancet. Infectious diseasesField evaluation of validity and feasibility of Pan-Lassa rapid diagnostic test for Lassa fever in Abakaliki, Nigeria: a prospective diagnostic accuracy study.
The Lancet. Infectious diseasesReservoir displacement by an invasive rodent reduces Lassa virus zoonotic spillover risk.
Nature communicationsDevelopment of a non-infectious control for viral hemorrhagic fever PCR assays.
PLoS neglected tropical diseasesRodent control strategies and Lassa virus: some unexpected effects in Guinea, West Africa.
Emerging microbes & infectionsTrend of Lassa fever cases and factors associated with mortality in Liberia, 2016 - 2021: a secondary data analysis.
The Pan African medical journalBalancing the uncertain and unpredictable nature of possible zoonotic disease transmission with the value placed on animals: Findings from a qualitative study in Guinea.
PLOS global public healthSpatio-temporal spread and evolution of Lassa virus in West Africa.
BMC infectious diseasesUntold Lassa fever story: a physician's lived experience.
The Lancet. Infectious diseasesPotential implications of the climate crisis on diagnostics.
PLOS global public healthMHC-I alleles mediate clearance and antibody response to the zoonotic Lassa virus in Mastomys rodent reservoirs.
PLoS neglected tropical diseasesBeyond the Shadows: Strengthening Nigeria's Health System in the Wake of Lassa Fever and Covid-19 Challenges.
West African journal of medicineAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Febre de Lassa.
É de uma associação que acompanha esta doença? Fale com a gente →
Comunidades
Grupos ativos de quem convive com esta doença aqui no Raras
Ainda não existe comunidade no Raras para Febre de Lassa
Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.
Tire suas dúvidas
Perguntas, dicas e experiências compartilhadas aqui na página
Participe da discussão
Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.
Fazer loginDoenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Referências e fontes
Bases de dados externas citadas neste artigo
Publicações científicas
Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.
- Development of a Conditional Replication System Using a Lassa Virus Glycoprotein Complex-Encoding Retroviral Vector for Isolating Resistant Variants to Inhibitors in BSL-2.
- Post-discharge sequelae of Lassa fever survivors in Nigeria: an analysis of the LASCOPE prospective cohort.
- Agnostic capture of pathogens for the detection and diagnostics of emerging threats.
- Health-economic impacts of age-targeted and sex-targeted Lassa fever vaccination in endemic regions of Nigeria, Guinea, Liberia, and Sierra Leone: a modelling study.
- Lassa fever symptomatology, viral dynamics, and host immune response (PREPARE): a prospective, observational cohort study in Liberia.
- The virus entry inhibitor ARN-75039 provides therapeutic protection against Lassa virus infection in guinea pigs.
- Neural network modeling of Lassa fever spread and disability effects.
- B cell immunity to the Lassa virus glycoprotein is a correlate of vaccination-induced virus control in mice.
- Post-acute sequelae after Lassa fever: A systematic review and meta-analysis.
- Development of a broad-lineage Lassa virus rapid diagnostic test informed by the WHO REASSURED framework.
Bases de dados e fontes oficiais
Identificadores e referências canônicas usadas para montar este verbete.
- ORPHA:99824(Orphanet)
- MONDO:0005820(MONDO)
- GARD:19688(GARD (NIH))
- Busca completa no PubMed(PubMed)
- Artigo Wikipedia(Wikipedia)
- Q706845(Wikidata)
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
